Yuko Mori

Yuko Mori

Auto-generated profile, based on publicly available information

Yuko Mori

Pfizer R&D Japan, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2021 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
YNYoichi Naito
Yoichi Naito
YKYasutoshi Kuboki
Yasutoshi Kuboki
MIMasafumi Ikeda
Masafumi Ikeda
KHKenichi Harano
Kenichi Harano
NMNobuaki Matsubara
Nobuaki Matsubara
TKTakahiro Kogawa
Takahiro Kogawa
Summary: Background: Talazoparib is a poly(ADP-ribose) polymerase enzyme inhibitor. This open-label, non-randomized, phase 1 study of talazoparib investigated the safety, pharmacokinetics, and preliminary antitumor activity in Japanese patients with locally advanced or metastatic solid tumors, regardless of mutations in DNA damage repair-related genes, who are resistant to/ineligible for standard therapies. Methods: Patients received talazoparib dosed orally at 0.75 or 1 mg once daily using a modified 3 + 3 dose-escalation scheme. Primary endpoint was dose-limiting toxicities during the first cycle of talazoparib. Results: Nine patients (median age 62.0 years) were included: 3 and 6 patients at the 0.75 and 1.0 mg once-daily dose levels, respectively. No dose-limiting toxicities were reported. The most commonly reported treatment-emergent adverse events (≥2 patients) were anemia, stomatitis, maculopapular rash, platelet count decreased, neutrophil count decreased, and alanine aminotransferase increased. Three patients had grade ≥ 3 treatment-emergent adverse events (anemia, brain metastases [1 patient each], and neutrophil and white blood cell count decreased [same patient]). Two patients temporarily discontinued treatment due to a treatment-emergent adverse event, and 1 patient required a dose reduction for neutrophil count decreased (all at 1 mg once daily). Talazoparib exposure (Cmax and AUC) after single and multiple dosing was slightly higher proportionally with talazoparib 1 mg than talazoparib 0.75 mg. The overall disease control rate was 44.4%, including 2 patients with stable disease. The recommended phase 2 dose of talazoparib was established as 1 mg once daily. Conclusions: Single-agent talazoparib was well tolerated and had preliminary antitumor activity in Japanese patients with advanced solid tumors. ClinicalTrials.gov identifier: NCT03343054 (November 17, 2017).

1 January 2004 in Koutou (The Larynx Japan)
Verified
Journal Article
Open access
PDF file
ASAkihiro Shiotani
Akihiro Shiotani
AIAsako Ikeda
Asako Ikeda
MTMasayuki Tomifuji
Masayuki Tomifuji
YMYuko Mori
Yuko Mori
TTTakuji Takaoka
Takuji Takaoka
KOKaoru Ogawa
Kaoru Ogawa
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。

30 July 2022 in Breast Cancer
Verified
Journal Article
Open access
PDF file
KKKotani Kotani
Kotani Kotani
Norikazu MasudaNorikazu Masuda
Norikazu Masuda
TYToshinari Yamashita
Toshinari Yamashita
YNYoichi Naito
Yoichi Naito
TTTetsuhiko Taira
Tetsuhiko Taira
HIHiroji Iwata
Hiroji Iwata
Background: Talazoparib, a poly(ADP-ribose) polymerase enzyme inhibitor, is approved for the treatment of patients with germline BRCA1/2 (gBRCA1/2)-mutated HER2-negative advanced breast cancer. This two-part study, a recently published dose-escalation part followed by the dose-expansion part reported here, evaluated the efficacy and safety of talazoparib in Japanese patients with gBRCA1/2-mutated advanced breast cancer. Methods: In this open-label, multicenter phase 1 study (NCT03343054), the primary endpoint of the dose-expansion part was confirmed objective response rate (ORR), determined by investigator assessment (RECIST 1.1). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and pharmacokinetics. Patients received the recommended phase 2 dose (1 mg/day; 0.75 mg/day moderate renal impairment). Results: Nineteen Japanese patients with gBRCA1/2-mutated locally advanced or metastatic breast cancer were enrolled. Confirmed ORR was 57.9% (11/19; 90% confidence interval [CI] 36.8–77.0). Stable disease was observed in 36.8% (7/19) of patients. Per investigator assessment, median PFS was 7.2 months (95% CI 4.1–not estimable) and 12-month OS rate was 84.7% (90% CI 57.5–95.1). Median OS was not reached; 17/19 patients were alive and censored at 12 months. All patients experienced treatment-related adverse events (AEs); the majority were hematologic. The most common treatment-related AE was anemia (68.4%; [13/19]). Grade 3/4 treatment-related AEs were observed in 52.6% (10/19) of patients. During the safety period, there were no grade 5 treatment-emergent AEs, treatment-related serious AEs, or deaths. Conclusions: In Japanese patients with gBRCA mutations and locally advanced or metastatic breast cancer, talazoparib monotherapy was generally well tolerated and resulted in clinically meaningful ORRs. Clinicaltrials.gov identifier: NCT03343054.

1 January 2001 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
YMYuko Mori
Yuko Mori
KHKazuhiko Hanada
Kazuhiko Hanada
TMTatsuya Mori
Tatsuya Mori
YTYoko Tsukahara
Yoko Tsukahara
MHMasayuki Hashiguchi
Masayuki Hashiguchi
HOHiroyasu Ogata
Hiroyasu Ogata
We have estimated the pharmacokinetic and pharmacodynamic interactions of verapamil (VP) enantiomers and also the interaction between VP and its metabolite, norverapamil (NVP). ECGs of conscious rabbits were studied to determine the pharmacokinetics of VP enantiomers and racemic NVP in relation to their prolongation effect on PR intervals, which were used as an index of VP's antiarrhythmic effect. Plasma free fractions of VP enantiomers showed constant values at concentrations ranging from 0.022 to 1.10 microm. There were no interactions between enantiomers or between VP and NVP. The pharmacological effect of the S-enantiomer (S-VP), which was determined by linear regression analysis, showed it was about 20 times more potent than that of the R-enantiomer (R-VP). The effect of racemic VP was the simple sum of those elicited by both enantiomers. These relationships were not significantly different between intravenous infusion and bolus injection. Simultaneous intravenous infusion of NVP had no influence on the PR intervals. In conclusion, we demonstrated that the relationship between plasma unbound concentration of VP enantiomers and their pharmacological effect was the simple sum of two enantiomers.

31 December 2024 in Cancer Medicine
Verified
Journal Article
Open access
NMNobuaki Matsubara
Nobuaki Matsubara
HMHideaki Miyake
Hideaki Miyake
HUHiroji Uemura
Hiroji Uemura
AMAtsushi Mizokami
Atsushi Mizokami
HKHiroaki Kikukawa
Hiroaki Kikukawa
HUHirotsugu Uemura
Hirotsugu Uemura
Background: In TALAPRO‐2, the poly(ADP‐ribose) polymerase inhibitor talazoparib plus the androgen receptor–signaling inhibitor enzalutamide improved radiographic progression‐free survival (rPFS) versus placebo plus enzalutamide (hazard ratio [HR] = 0.63; 95% CI, 0.51–0.78) in molecularly unselected patients with metastatic castration‐resistant prostate cancer (mCRPC). We report an exploratory analysis of efficacy, safety, and pharmacokinetics in Japanese patients enrolled in the TALAPRO‐2 study. Methods: The ongoing, multinational, randomized, double‐blind, phase 3 TALAPRO‐2 study enrolled patients with mCRPC receiving ongoing androgen deprivation therapy. Patients were prospectively assessed for homologous recombination repair (HRR) gene alterations and randomized 1:1 to receive talazoparib or placebo plus enzalutamide once daily. The primary endpoint was rPFS by blinded independent central review (BICR). Secondary endpoints included overall survival, objective response, safety, and pharmacokinetics. Results: For the 116 Japanese all‐comers patients enrolled in TALAPRO‐2, the HR for rPFS was 0.89 (95% CI, 0.45–1.75) for the talazoparib versus placebo arm; among those with HRR‐deficient disease, the HR was 0.58 (95% CI, 0.16–2.20). Among patients with BRCA1/2 gene alterations in the HRR‐deficient population ( n = 10), the HR for rPFS was < 0.01 (95% CI, < 0.01–not reached) for the talazoparib versus placebo arm. In the all‐comers population, the objective response rate by BICR was 55% (all complete responses) in the talazoparib arm versus 36% in the placebo arm. The safety profile of talazoparib plus enzalutamide was similar between Japanese patients and the overall all‐comers population; no new safety signals were identified. Anemia was the most common grade 3/4 treatment‐emergent adverse event (55%) and cause of talazoparib discontinuation (12%). Talazoparib C trough was comparable across Japanese, Asian, and non‐Asian subgroups. Conclusions: In this exploratory analysis, efficacy outcomes with talazoparib plus enzalutamide in Japanese patients in TALAPRO‐2 were consistent with those in the overall all‐comers population. The safety profile and pharmacokinetics of the combination were similar between Japanese patients and the overall all‐comers population. Trial Registration: ClinicalTrials.gov Identifier: NCT03395197

11 October 2021 in The Japanese Economic Review
Verified
Journal Article
Open access
PDF file
JGJun Goto
Jun Goto
TKTakashi Kurosaki
Takashi Kurosaki
YMYuko Mori
Yuko Mori
While recent empirical evidence reveals some effective interventions in preventing corruption among bureaucrats and politicians, there has been little discussion on how to prevent the bribe-giving behavior of ordinary citizens. This paper investigates the role of social media information in influencing the supply of bribes by citizens instead of the demand side. We, therefore, developed and published an original news application in India and implemented a 3-month experiment. In this application, we randomly circulate live news related to corruption to users and incorporate a lab experiment into the app system to elicit users’ bribery behavior every week. We find that corruption news involving politicians within a close geographical proximity lowers users’ moral costs against the anti-social bribery act, leading to an increase in the amount of bribes. However, news of accused citizens and officials within the geographic proximity increases their moral cost against bribes and decreases the amount. This suggests that individually tailored local information on corruption may be an effective tool to reduce citizens’ supply of bribes.